| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
We introduced MLL rearranged fusion gene into CD10 positive leukemic cell line. At first, we thought CD10 expression would shut down after transduction as typical infantile MLL-rearranged lymphocytic leukemia. However, CD10 did not turn into negative. The other factors would be related to this CD10 negativity phenomenon.
Next, we experienced congenital acute myeloid leukemia case who got into spontaneous remission without any therapy. We checked DNA, RNA and protein expression level and realized that RNA and protein expression levels were extremely low compared to DNA. This suppression phenomenon has not been reported so far. Continuous examination of this mechanism would shed light on the establishment the novel treatment strategy of refractory infantile leukemia.
|
